High-Risk Retinoblastoma Based on International Classification Systems: Analysis of 1362 Eyes.

IF 4.4 Q1 OPHTHALMOLOGY
Deepthi E Kurian, Swathi Kaliki, Carol L Shields
{"title":"High-Risk Retinoblastoma Based on International Classification Systems: Analysis of 1362 Eyes.","authors":"Deepthi E Kurian, Swathi Kaliki, Carol L Shields","doi":"10.1016/j.oret.2025.01.020","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To determine the predictive value of International Intraocular Retinoblastoma Classification schemes and the American Joint Committee on Cancer (AJCC) classification for histopathological high-risk features (HRFs).</p><p><strong>Design: </strong>Multicentric international collaborative retrospective case series.</p><p><strong>Subjects: </strong>One thousand three hundred and sixty-two patients with retinoblastoma from 16 centers and 11 countries.</p><p><strong>Intervention: </strong>Primary enucleation; adjuvant therapy in patients with HRF.</p><p><strong>Main outcome measures: </strong>High-risk retinoblastoma defined as 1 or more HRF (anterior segment involvement, massive choroidal invasion, minor choroidal infiltration with prelaminar optic nerve invasion, retrolaminar or resected optic nerve cut end involvement, scleral or microscopic extrascleral infiltration); metastasis-free survival (MFS).</p><p><strong>Results: </strong>Of the 1362 patients, 751 (55.1%) had HRF. According to the International Classification of Retinoblastoma (ICRB) (Philadelphia vs. Los Angeles [LA]) versus Children's Oncology Group (COG) classification schemes, the positive predictive value (PPV) of group D eyes for HRF was 42.0% versus 35.1% versus 43.2%, respectively, and that for group E eyes was 58.5% versus 59.0% versus 59.5%, respectively. Comparing group D versus group E eyes, there was higher mean number of HRF (standard deviation, range) among group E eyes using the ICRB Philadelphia (0.7 [0.9, 0.0-6.0] vs. 1.3 [1.7, 0.0-9.0], P < 0.001), ICRB LA (0.6 [0.8, 0.0-6.0] vs. 1.3 [1.7, 0.0-9.0], P < 0.001) and COG (0.8 [1.2, 0.0-7.0] vs. 1.3 [1.6, 0.0-8.0], P < 0.001) classifications. The PPV for HRF was above 55% for AJCC clinical tumor (cT) group cT3a with increments through cT3e to 72.3%. An agreement between ICRB Philadelphia versus ICRB LA, ICRB LA versus COG, and ICRB Philadelphia versus COG was 0.9, 0.8, and 0.8, respectively (P < 0.001). Metastasis-free survival rates and overall survival rates were also comparable between all intraocular retinoblastoma classification schemes but better stratified within the AJCC scheme.</p><p><strong>Conclusions: </strong>All intraocular retinoblastoma classification schemes predict HRF and MFS equally. Group E includes a wide spectrum equivalent to the AJCC group cT3. Uniform grouping with subcategorization of group E might improve risk stratification. We propose that everyone across the retinoblastoma world henceforth adopts the AJCC classification for all reporting and publishing.</p><p><strong>Financial disclosure(s): </strong>The authors have no proprietary or commercial interest in any materials discussed in this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2025.01.020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To determine the predictive value of International Intraocular Retinoblastoma Classification schemes and the American Joint Committee on Cancer (AJCC) classification for histopathological high-risk features (HRFs).

Design: Multicentric international collaborative retrospective case series.

Subjects: One thousand three hundred and sixty-two patients with retinoblastoma from 16 centers and 11 countries.

Intervention: Primary enucleation; adjuvant therapy in patients with HRF.

Main outcome measures: High-risk retinoblastoma defined as 1 or more HRF (anterior segment involvement, massive choroidal invasion, minor choroidal infiltration with prelaminar optic nerve invasion, retrolaminar or resected optic nerve cut end involvement, scleral or microscopic extrascleral infiltration); metastasis-free survival (MFS).

Results: Of the 1362 patients, 751 (55.1%) had HRF. According to the International Classification of Retinoblastoma (ICRB) (Philadelphia vs. Los Angeles [LA]) versus Children's Oncology Group (COG) classification schemes, the positive predictive value (PPV) of group D eyes for HRF was 42.0% versus 35.1% versus 43.2%, respectively, and that for group E eyes was 58.5% versus 59.0% versus 59.5%, respectively. Comparing group D versus group E eyes, there was higher mean number of HRF (standard deviation, range) among group E eyes using the ICRB Philadelphia (0.7 [0.9, 0.0-6.0] vs. 1.3 [1.7, 0.0-9.0], P < 0.001), ICRB LA (0.6 [0.8, 0.0-6.0] vs. 1.3 [1.7, 0.0-9.0], P < 0.001) and COG (0.8 [1.2, 0.0-7.0] vs. 1.3 [1.6, 0.0-8.0], P < 0.001) classifications. The PPV for HRF was above 55% for AJCC clinical tumor (cT) group cT3a with increments through cT3e to 72.3%. An agreement between ICRB Philadelphia versus ICRB LA, ICRB LA versus COG, and ICRB Philadelphia versus COG was 0.9, 0.8, and 0.8, respectively (P < 0.001). Metastasis-free survival rates and overall survival rates were also comparable between all intraocular retinoblastoma classification schemes but better stratified within the AJCC scheme.

Conclusions: All intraocular retinoblastoma classification schemes predict HRF and MFS equally. Group E includes a wide spectrum equivalent to the AJCC group cT3. Uniform grouping with subcategorization of group E might improve risk stratification. We propose that everyone across the retinoblastoma world henceforth adopts the AJCC classification for all reporting and publishing.

Financial disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Ophthalmology. Retina
Ophthalmology. Retina Medicine-Ophthalmology
CiteScore
7.80
自引率
6.70%
发文量
274
审稿时长
33 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信